Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency

@inproceedings{Nilsson2014ProspectiveEO,
  title={Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency},
  author={Anna G. Nilsson and Claudio Marelli and David Fitts and Ragnhildur Bergthorsdottir and Pia Burman and Per Dahlqvist and Bertil Ekman and Britt Ed{\'e}n Engstr{\"o}m and Tommy Olsson and Oskar Ragnarsson and Marianne Ryberg and Jeanette Wahlberg and Hans Lennernaes and Stanko Skrtic and Gudmundur Johannsson},
  booktitle={European journal of endocrinology},
  year={2014}
}
OBJECTIVE The objective was to assess the long-term safety profile of dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI). DESIGN Randomised, open-label, crossover trial of DR-HC or thrice-daily hydrocortisone for 3 months each (stage 1) followed by two consecutive, prospective, open-label studies of DR-HC for 6 months (stage 2) and 18 months (stage 3) at five university clinics in Sweden. METHODS Sixty-four adults with primary AI started stage 1, and an… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
11 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…